LLM BSc - Purple Biotech Vice Operations
| PPBT Stock | USD 2.98 0.13 4.56% |
Executive
LLM BSc is Vice Operations of Purple Biotech
| Age | 53 |
| Address | 4 Oppenheimer Street, Rehovot, Israel, 7670104 |
| Phone | 972 3 933 3121 |
| Web | https://purple-biotech.com |
Purple Biotech Management Efficiency
The company has return on total asset (ROA) of (0.2497) % which means that it has lost $0.2497 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3439) %, meaning that it created substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.57 in 2025, whereas Return On Tangible Assets are likely to drop (0) in 2025. At this time, Purple Biotech's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 3.4 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 32.4 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robert JD | Pmv Pharmaceuticals | 63 | |
| Patricia Hirano | Soleno Therapeutics | 58 | |
| MD MBA | SAB Biotherapeutics | 53 | |
| Daniel George | Anebulo Pharmaceuticals | 55 | |
| FCA BEC | Bionomics Ltd ADR | 72 | |
| Kristen MS | Soleno Therapeutics | 56 | |
| Meredith MBA | Soleno Therapeutics | 52 | |
| John Dvor | Pluri Inc | N/A | |
| Jeffrey Cole | Cadrenal Therapeutics, Common | N/A | |
| Liat Zalts | Pluri Inc | 41 | |
| MBA MBA | Bio Path Holdings | N/A | |
| Efrat LivneHadass | Pluri Inc | N/A | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Veronique AmorBaroukh | Enlivex Therapeutics | N/A | |
| Efrat Kaduri | Pluri Inc | N/A | |
| Lauren Budesheim | Soleno Therapeutics | N/A | |
| Michael Carulli | Pmv Pharmaceuticals | 51 | |
| MBA Ashizawa | Bio Path Holdings | N/A | |
| Jesse Schumaker | Soleno Therapeutics | N/A | |
| Mark Conley | SAB Biotherapeutics | N/A | |
| Jennifer Callahan | Cingulate | 53 | |
Management Performance
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.25 |
Purple Biotech Leadership Team
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MA CPA, Chief Officer | ||
| Fabien Sebille, Chief Officer | ||
| Michael Schickler, Head Affairs | ||
| LLM BSc, Vice Operations | ||
| Ido Morpurgo, VP Operations | ||
| Nir Livneh, VP Affairs |
Purple Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 1.72 M | ||||
| Shares Outstanding | 2.58 M | ||||
| Shares Owned By Insiders | 1.98 % | ||||
| Shares Owned By Institutions | 3.03 % | ||||
| Number Of Shares Shorted | 53.98 K | ||||
| Price To Book | 0.26 X | ||||
| Price To Sales | 58.08 X | ||||
| Gross Profit | (196 K) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.